We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Kofax | KFX | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 735.00 | 00:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 735.00 | 735.00 |
| Top Posts |
|---|
Posted at 04/10/2013 07:18 by aishah Very positive. Expect US investors to chase these when listed there. Techinvest are huge fans having addded to their portfolio twice. Dyor |
Posted at 05/9/2013 11:16 by b1ggles Fewbob, it would be a pretty rum do if they bought shares for their investors yet they weren't good enough to recommend in the tipsheet!They've made me a samll fortune over the last few years. |
Posted at 05/9/2013 07:14 by starfishprime Thanks Bo - I have never heard of a DR, then I am new to all this.A Depositary Receipt is a negotiable U.S. security that generally represents a company's publicly traded equity or debt. Depositary Receipts are created when a broker purchases a non-U.S. company's shares on its home stock market and delivers the shares to the depositary's local custodian bank, and then instructs the depositary bank, such as BNY Mellon, to issue Depositary Receipts. In addition, Depositary Receipts may also be purchased in the U.S. secondary trading market. They may trade freely, just like any other security, either on an exchange or in the over-the-counter market and can be used to raise capital. Depositary Receipts may be more specifically called American Depositary Receipts (ADRs), Rule 144A Depositary Receipts or Global Depositary Receipts (GDRs). These names typically identify the market in which the Depositary Receipts are available: ADRs are publicly available to U.S. investors on a national stock exchange or in the over-the-counter market; Rule 144A ADRs are privately placed and resold only to Qualified Institutional Buyers (QIBs) in the U.S. QIB PORTAL market; and GDRs are generally available in one or more markets outside the foreign company's home country, although these may also be known as ADRs. Benefits to a Company Currently, there are over 2,250 Depositary Receipt programs for companies from over 70 countries. The establishment of a Depositary Receipt program offers numerous advantages to non-U.S.companies. The primary reasons to establish a Depositary Receipt program can be divided into two broad considerations: capital and commercial. Advantages may include: Expanded market share through broadened and more diversified investor exposure with potentially greater liquidity, which may increase or stabilize the share price. Enhanced visibility and image for the company's products, services and financial instruments in a marketplace outside its home country. Flexible mechanism for raising capital and a vehicle or currency for mergers and acquisitions. Enables employees of U.S. subsidiaries of non-U.S. companies to invest more easily in the parent company. So if correct either a broker will buy a shed load of shares off LSE or Co will issue more direct to holding bank to either raise funds for merger/acquisition. They must have something in mind to spend the fees and they already have plenty of cash. |
Posted at 04/9/2013 17:11 by starfishprime Other Operating Expense, net - Other operating expenses, net increased $1.7 million, or 258.0% to $2.4 million in the fiscal year ended June 30, 2013 due to professional fees incurred for attorneys, accountants and other advisors associated with the preliminary work needed for us to complete a United States listing of all common shares. The above was in the accounts. Does this mean they are leaving LSE? I assume common = ordinary shares.If so what are the implications for current investors? |
Posted at 01/8/2011 19:12 by tsmith2 SG broker stances after last week..I've also heard that a speculative bid may well be in the offing given the price action, just a rumour I've heard canaccord - BUY £5.5 TP Jeffries - BUY £5.98 TP ALtium - Down Hold £5p TP CAN.. Kofax: Mkt reaction overdone, believe KFX is a STRONG BUY at these levels... - Investor reaction to Trading update has been overly negative in our view - We have been through our model with the Co and are comfortable with our Nos - FY11 Revs expected to be in the range of $244-246m v our $246m but below Kofax's 14% org constant currency Rev growth target - KFX seeing slower sales cycle due to continuing uncertainty in the global macroeconomic environment but we don't expect further deterioation in outlook - We raise our expense est slightly due to currency effects and trim EBITA est - Trimming FY11 from $246m to $245m; EBITA cut from $43.4m to $42.0m - Trimming FY12 from $268m to $267m; EBITA cut from $49.6m to $48.0m - Net cash was ahead as of 30 June at $98m v our $95.5m and has substantial acquisition opportunites - Separatley, Harvey Spencer Associates published a report on "The 2011-2012 Worldwide Market for Document Capture Software," in which is est KFX rose to 15% share in 2010 from 11% the prior year - We remain confident of 14% growth in FY12 Adj Op Profit - Trading at 10x FY12 EV/Op Profit or 15x Ex-cash FY12 EPS Reit BUY, PT 550p |
Posted at 01/8/2011 11:26 by pre tsmith2 - 1 Aug'11 - 11:10 - 292 of 295 canaccord - BUY £5.5 TP Jeffries - BUY £5.98 TP ALtium - Down Hold £5p TP CAN.. Kofax: Mkt reaction overdone, believe KFX is a STRONG BUY at these levels... - Investor reaction to Trading update has been overly negative in our view - We have been through our model with the Co and are comfortable with our Nos - FY11 Revs expected to be in the range of $244-246m v our $246m but below Kofax's 14% org constant currency Rev growth target - KFX seeing slower sales cycle due to continuing uncertainty in the global macroeconomic environment but we don't expect further deterioation in outlook - We raise our expense est slightly due to currency effects and trim EBITA est - Trimming FY11 from $246m to $245m; EBITA cut from $43.4m to $42.0m - Trimming FY12 from $268m to $267m; EBITA cut from $49.6m to $48.0m - Net cash was ahead as of 30 June at $98m v our $95.5m and has substantial acquisition opportunites - Separatley, Harvey Spencer Associates published a report on "The 2011-2012 Worldwide Market for Document Capture Software," in which is est KFX rose to 15% share in 2010 from 11% the prior year - We remain confident of 14% growth in FY12 Adj Op Profit - Trading at 10x FY12 EV/Op Profit or 15x Ex-cash FY12 EPS Reit BUY, PT 550p |
Posted at 01/8/2011 10:10 by tsmith2 canaccord - BUY £5.5 TPJeffries - BUY £5.98 TP ALtium - Down Hold £5p TP CAN.. Kofax: Mkt reaction overdone, believe KFX is a STRONG BUY at these levels... - Investor reaction to Trading update has been overly negative in our view - We have been through our model with the Co and are comfortable with our Nos - FY11 Revs expected to be in the range of $244-246m v our $246m but below Kofax's 14% org constant currency Rev growth target - KFX seeing slower sales cycle due to continuing uncertainty in the global macroeconomic environment but we don't expect further deterioation in outlook - We raise our expense est slightly due to currency effects and trim EBITA est - Trimming FY11 from $246m to $245m; EBITA cut from $43.4m to $42.0m - Trimming FY12 from $268m to $267m; EBITA cut from $49.6m to $48.0m - Net cash was ahead as of 30 June at $98m v our $95.5m and has substantial acquisition opportunites - Separatley, Harvey Spencer Associates published a report on "The 2011-2012 Worldwide Market for Document Capture Software," in which is est KFX rose to 15% share in 2010 from 11% the prior year - We remain confident of 14% growth in FY12 Adj Op Profit - Trading at 10x FY12 EV/Op Profit or 15x Ex-cash FY12 EPS Reit BUY, PT 550p |
Posted at 28/7/2011 21:31 by wylecoyote Am I right in understanding that the sell off may be a little overdone? Investors are a little twitchy these days. Still, I will watch this and try and spot and opportunity. |
Posted at 06/7/2011 16:51 by matt123d Below is the most recent.Wire: Business Wire (BUS) Date: Jul 5 2011 9:00:00 Medical Research Firm Selects Kofax for Invoice Processing Solution Medical Research Firm Selects Kofax for Invoice Processing Solution Software to Automate the Processing of 300,000 Invoices Annually Business Wire IRVINE, Calif. -- July 05, 2011 Kofax plc (LSE: KFX), the leading provider of document driven business process automation solutions, today announced that a leading medical research firm and provider of pharmaceutical, clinical and other consulting services has selected Kofax for its invoice processing solution. The value of the contract to Kofax exceeds $800,000. The customer will implement Kofax Capture, Kofax Transformation Modules, Kofax Front Office Server and MarkView for Accounts Payable to automate the processing of approximately 300,000 invoices and other accounts payable related documents it receives annually. Once processed, invoice images and data will be routed to an Oracle repository for easy access. The overall solution will better data accuracy, accelerate the processing of multilingual invoices and significantly reduce the cost of manual tasks. "By capturing and transforming paper invoices into digitized information as they enter an enterprise, customers can streamline the entire accounts payable process from end-to-end and quickly realize an ROI through reduced errors, faster processing times and improved cash management," said Alan Kerr, Executive Vice President of Field Operations at Kofax. Kofax Capture provides industry leading scan-to-archive capabilities by scanning documents and forms to create digital images, extracting index data for retrieval purposes and delivering the images and associated data to a variety of repositories and applications. This can significantly reduce retrieval costs while improving better regulatory and compliance efforts. Kofax Capture is flexible and scalable, enabling customers to define where and how images are captured and indexed, whether in a home office, remote branch or back office data center. Kofax Transformation Modules (KTM) adds document and form classification, page separation, challenging data extraction and validation capabilities to Kofax Capture and provides robust scan-to-process applications. By automating what was previously labor intensive, error prone and time consuming tasks, it can significantly reduce labor costs, improve information quality and accelerate business processes. Kofax Front Office Server extends existing Kofax Capture applications by allowing customer facing employees in front office environments to initiate scanning and index data extraction processes at the earliest point of contact to accelerate business processes, gain competitive advantage and leverage existing MFP and desktop scanning resources in remote or branch offices. This office automation solution reduces latency and eliminates the time and cost of shipping documents to centralized processing centers. MarkView for Accounts Payable is a comprehensive, capture enabled financial process automation application for accounts payable and other functions. It automates the receipt and capture of paper and electronic invoices, performs data extraction and perfection, and manages workflows for routing transactions through exception handling and approval processes, significantly reducing cycle times and costs while optimizing process control and cash flow management. About Kofax Kofax plc (LSE: KFX) is the leading provider of document driven business process automation solutions. For more than 20 years, Kofax has provided award winning solutions that streamline the flow of information throughout an organization by managing the capture, transformation and exchange of business critical information arising in paper, fax and electronic formats in a more accurate, timely and cost effective manner. These solutions provide a rapid return on investment to thousands of customers in financial services, government, business process outsourcing, healthcare, supply chain and other markets. Kofax delivers these solutions through its own sales and service organizations, and a global network of more than 700 authorized partners in more than 60 countries throughout the Americas, EMEA and Asia Pacific. For more information, visit www.kofax.com. "Kofax" is a registered trademark in the US, the EU and other regions. All other trademarks and registered trademarks are the property of their respective owners. Contact: Kofax plc Investor Contact: Jamie Arnold, +1 949-783-1473 Chief Financial Officer jamie.arnold@kofax.c or Media Contact: Rob Jensen, +1 949-783-1295 Senior Director, Corporate Communications rob.jensen@kofax.com -0- Jul/05/2011 08:00 GMT |
Posted at 16/6/2010 08:45 by sportbilly1976 the rns is slighty wrong though...if you look at the trade, the 150k at 235p was on the 9th June not the 10th.Although if you look at the trades that day, we might see a couple more director dealing / holding rns' possibly...?? |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
